The abstract is read at the publisher; the summary is JClub's.
In IMmotion010 high-risk localized renal cell carcinoma, matched primary and recurrent tumors show recurrence-linked shifts in proliferation, fatty acid synthesis, stromal biology, and immune programs, including MHC-I downregulation after adjuvant atezolizumab.
- Why it matters: Recurrence after nephrectomy is common, but the genomic and transcriptomic changes distinguishing primary from recurrent tumors—and how they differ by adjuvant therapy—remain unclear.
- What they did: The study analyzed tumor tissue from IMmotion010 at baseline (n = 754) and at recurrence (n = 80), performing matched transcriptomic (n = 80) and genomic (n = 52) profiling of primary versus recurrent samples.
- The result: Primary tumors had more angiogenic and small nucleolar RNA signatures and less T-effector/proliferative and stromal/proliferative content than published metastatic cohorts; recurrent sites upregulated proliferation, fatty acid synthesis, and stromal signatures, with placebo recurrences showing higher B cell/macrophage signatures and atezolizumab recurrences showing MHC-I downregulation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.